Search Results

Vycellix, Inc. today announced that its founding Chairman & CEO, Evren Alici, M.D., Ph.D., presented pre-clinical, proof-of-concept results for the Company’s single-step approach to engineer allogeneic cells (VY-UC) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in Paris.

Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that members of its executive leadership team are scheduled to present and moderate panel sessions at the following upcoming life science conferences this week

Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products. The companies will collaborate on the delivery of Vycellix’s novel RNA immunomodulator VY-M using Avectas’ cell

Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Allogeneic Cell Therapies Summit.

Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, has appointed the inaugural members of its Scientific Advisory Board (SAB).

Avectas, a cell engineering technology business and Vycellix, Inc. an immuno-discovery cell & gene therapy company, today announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products. The companies will collaborate on the de

VY-UC represents novel & simplified approach to design “off-the-shelf” therapies resolving the complexities & limitations of gene-editing to modulate self-recognition proteins TAMPA, Fla. & STOCKHOLM--( BUSINESS WIRE )-- Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the

The Vycellix team, which will initially include its senior executive and administrative staff, is scheduled to occupy the new space adjacent to the Moffitt Cancer Center in April.

Vycellix™, Inc. announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will establish its U.S. headquarters in Tampa, Florida.

Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners